ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$268.19|
|52 Week High||US$168.76|
|52 Week Low||US$271.51|
|1 Month Change||11.47%|
|3 Month Change||26.40%|
|1 Year Change||51.37%|
|3 Year Change||78.50%|
|5 Year Change||250.67%|
|Change since IPO||4,117.16%|
Recent News & Updates
ICON PLC: An Easy Stock To Choose For Diversified Exposure To Healthcare And Clinical Research
ICON Public Limited Company is a leading clinical research organization, aiding researchers and companies across the entire industry in performing their work. The healthcare industry is extremely strong at the moment and set to see favorable tailwinds over the next few years. I believe ICON has been shrewd in its management and growth so far and is a low-risk investment for any investor.
Does ICON (NASDAQ:ICLR) Deserve A Spot On Your Watchlist?
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
|ICLR||US Life Sciences||US Market|
Return vs Industry: ICLR exceeded the US Life Sciences industry which returned 49.4% over the past year.
Return vs Market: ICLR exceeded the US Market which returned 33.6% over the past year.
Stable Share Price: ICLR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: ICLR's weekly volatility (4%) has been stable over the past year.
About the Company
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services.
Is ICON undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: ICLR ($268.19) is trading above our estimate of fair value ($261.8)
Significantly Below Fair Value: ICLR is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: ICLR is poor value based on its PE Ratio (58.7x) compared to the US Life Sciences industry average (51.7x).
PE vs Market: ICLR is poor value based on its PE Ratio (58.7x) compared to the US market (17.8x).
Price to Earnings Growth Ratio
PEG Ratio: ICLR is poor value based on its PEG Ratio (3.4x)
Price to Book Ratio
PB vs Industry: ICLR is overvalued based on its PB Ratio (10.5x) compared to the US Life Sciences industry average (5.9x).
How is ICON forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ICLR's forecast earnings growth (17.5% per year) is above the savings rate (2%).
Earnings vs Market: ICLR's earnings (17.5% per year) are forecast to grow faster than the US market (14.8% per year).
High Growth Earnings: ICLR's earnings are forecast to grow, but not significantly.
Revenue vs Market: ICLR's revenue (18.9% per year) is forecast to grow faster than the US market (9.7% per year).
High Growth Revenue: ICLR's revenue (18.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ICLR's Return on Equity is forecast to be high in 3 years time (31.4%)
How has ICON performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ICLR has high quality earnings.
Growing Profit Margin: ICLR's current net profit margins (11.4%) are lower than last year (11.7%).
Past Earnings Growth Analysis
Earnings Trend: ICLR's earnings have grown by 7.1% per year over the past 5 years.
Accelerating Growth: ICLR's earnings growth over the past year (12.4%) exceeds its 5-year average (7.1% per year).
Earnings vs Industry: ICLR earnings growth over the past year (12.4%) underperformed the Life Sciences industry 55.2%.
Return on Equity
High ROE: ICLR's Return on Equity (17.9%) is considered low.
How is ICON's financial position?
Financial Position Analysis
Short Term Liabilities: ICLR's short term assets ($2.3B) exceed its short term liabilities ($1.1B).
Long Term Liabilities: ICLR's short term assets ($2.3B) exceed its long term liabilities ($451.5M).
Debt to Equity History and Analysis
Debt Level: ICLR's debt to equity ratio (17.3%) is considered satisfactory.
Reducing Debt: ICLR's debt to equity ratio has reduced from 38.3% to 17.3% over the past 5 years.
Debt Coverage: ICLR's debt is well covered by operating cash flow (156.5%).
Interest Coverage: ICLR's interest payments on its debt are well covered by EBIT (14.8x coverage).
What is ICON current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ICLR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ICLR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ICLR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ICLR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ICLR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Steve Cutler (61 yo)
Dr. Steven A. Cutler, also known as Steve, Ph D., MBA, has been the Chief Executive Officer of ICON Public Limited Company since March 01, 2017. Dr. Cutler is the Chief Operating Officer of ICON at ICON Cl...
CEO Compensation Analysis
Compensation vs Market: Steve's total compensation ($USD8.30M) is about average for companies of similar size in the US market ($USD11.33M).
Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.
Experienced Management: ICLR's management team is seasoned and experienced (5.2 years average tenure).
Experienced Board: ICLR's board of directors are considered experienced (4.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 51.4%.
ICON Public Limited Company's employee growth, exchange listings and data sources
- Name: ICON Public Limited Company
- Ticker: ICLR
- Exchange: NasdaqGS
- Founded: 1990
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$21.371b
- Shares outstanding: 79.69m
- Website: https://www.iconplc.com
Number of Employees
- ICON Public Limited Company
- South County Business Park
- Co. Dublin
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/18 00:48|
|End of Day Share Price||2021/09/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.